Heart shield? statin may guard against chemo damage

NCT ID NCT07668076

Completed Disease control Sponsor: Damanhour University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether atorvastatin, a cholesterol-lowering drug, can protect the heart in breast cancer patients receiving doxorubicin-based chemotherapy. 44 women with newly diagnosed breast cancer took atorvastatin daily for 3 months alongside their chemo. Researchers measured heart stress markers in the blood to see if the drug reduced heart damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atorvastatin
What this could lead to: If it works, this could point toward a way to reduce heart damage from doxorubicin chemotherapy in breast cancer patients.
What could go wrong: This is a small, early-phase study with only 44 participants. Results may not apply to all patients, and the heart-protective effect may be minimal or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm doxorubicin induced cardiomyopathy prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER DOXORUBICIN INDUCED CARDIOMYOPATHY

Contacts and locations

Locations

Damanhour university

Beheira, Damanhour, 22511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.